Research programme: PASylated therapeutics - Ajinomoto Bio-Pharma Services/XL-protein GmbH
Alternative Names: Metabolic disorders therapeutics - Ajinomoto Bio-Pharma Services/XL-protein GmbH; PASylated GLP-1 variant - Ajinomoto Bio-Pharma Services/XL-protein GmbHLatest Information Update: 28 Jan 2023
At a glance
- Originator Ajinomoto; XL-protein GmbH
- Class
- Mechanism of Action Glucagon-like peptide-1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Metabolic-disorders in Belgium
- 28 Jan 2023 No recent reports of development identified for preclinical development in Metabolic-disorders in Germany
- 18 Dec 2018 Ajinomoto Bio-Pharma Services and XL-protein GmbH enter into a strategic alliance to develop PASylated therapeutics for Metabolic disorders